Sector Imager 6000 Plate Reader

Sector Imager 6000 读板器

• 批准号: 8050230
• 负责人: JOHN C HUTTON
• 金额: $ 19万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-19 至 2012-08-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8050230
• 关键词: Animal Model; Autoantibodies; Autoimmune Diabetes; Autoimmune Diseases; Autoimmunity; Biological Assay; Biological Markers; Calibration; Centers for Disease Control and Prevention (U.S.); Childhood; Data; Detection; Diabetes Mellitus; Diagnosis; Disease; Environment; Funding; General Population; Goals; Grant; Housing; Human; Immunology; Individual; International; Investigational Therapies; Laboratories; Maintenance; Minor; Noise; Pathogenesis; Patients; Performance; Play; Quality Control; Radioisotopes; Reader; Reagent; Recruitment Activity; Risk; Role; Running; Scintillation Counter; Services; Signal Transduction; Societies; Speed; Standardization; Technology; Testing; Time; Translational Research; United States National Institutes of Health; Validation; cytokine; disease natural history; genetic analysis; instrument; micro-total analysis system; programs; research and development; research study; rituximab

DESCRIPTION (provided by applicant): The following proposal for the purchase of a Sector Imager 6000 Electrochemiluminescence plate reader is directed towards developing a high throughput shared facility for the analysis of immunological biomarkers of autoimmune disease and in particular autoantibodies and cytokines that play a role in the diagnosis and pathogenesis of type 1 autoimmune diabetes in humans. The Barbara Davis Center for Childhood Diabetes, where the instrument will be housed, is one of six reference laboratories in the world for the analysis of autoantibodies in new-diagnosed patients and for the identification of autoantibody positive individuals at risk of developing disease. The latter have been recruited into numerous national and international translational research studies following the natural history of the disease (DPT-1, TrialNet) and trails of experimental therapies (recently MMF, Rituximab, Bayhill). The SECTOR(R) Imager 6000 is extremely adaptable to a multiuser, multi-assay format without the need for calibration, resetting instrument parameters as well as being easily accessible compared to instruments such as scintillation counters and flow cytometers that are used in many of the current assays. It is now possible through the use of autoantibody testing combined with genetic analysis to identify individuals at risk of developing the disease from the general population however to achieve this goal there is a need to implement autoantibody assays using new formats that do not use radioisotopes yet can provide quantitative data that can be reproduced in multiple laboratories in very different operating environments all over the world. The MSD technology we contend is an excellent choice in that it brings us to the forefront of technology, yet provides a platform that is versatile and can be used for research and development of new assays and at the same time will be transplantable to fully-automated lab-on-a-chip assays that might ultimately be used as a point of service assay. Electrochemiluminescence detection affords distinct advantages in terms of speed, signal to noise and wide dynamic range over radiometric and photometric technologies. The ability to multiplex up to 10 analytes per well on prespotted plates is a significant saving in terms of reagents and operator time. The following proposal identifies a group of 4 major users involved in translational research and routine assay performance (70% instrument use) and 7 minor users (30% instrument use) who will principally use the machine for experimental research in animal models and in the research and development of new biomarkers of disease. Support from 20 NIH funded grants is documented ranging from several multicenter consortia to DERC pilot and feasibility grant holders. A plan for management and maintenance of the instrument is provided. Validation and quality control of the assays will be performed through our existing participation in the Diabetes Autoimmunity Standardization Program run from the Center of Disease control through the Immunology of Diabetes Society.

描述（由申请人提供）：购买扇形成像仪的以下建议6000电化学发光板读取器旨在开发高吞吐量共享设施，以分析自身免疫性疾病的免疫生物标志物，特别是自身抗体和细胞因子，尤其是在诊断和发挥作用的自动抗体和发挥作用。芭芭拉·戴维斯（Barbara Davis）儿童糖尿病中心（将要容纳该仪器的糖尿病中心）是世界上六个参考实验室之一，用于分析新诊断的患者的自身抗体，并鉴定出患有疾病风险的自身抗体阳性个体。在这种疾病的自然史（DPT-1，试验网）和实验疗法（最近MMF，MMF，Rituximab，Bayhill）之后，后者已被招募到许多国家和国际转化研究中。与闪烁计数器和诸如许多当前测定中使用的闪烁式计数器和流式细胞仪相比，该扇区（R）成像器6000极无需校准，重置仪器参数而无需进行校准，重置仪器参数，并且易于访问，并且容易访问。现在，通过使用自身抗体测试与遗传分析相结合，可以识别有可能从普通人群中发展该疾病的人，但是要实现这一目标，需要使用不使用放射性分析的新格式实施自身抗体测定，但可以提供定量数据，但可以提供可以在全世界的多个运营环境中在多个不同的运营环境中复制的定量数据。我们争夺的MSD技术是一个绝佳的选择，因为它使我们进入了技术的最前沿，但提供了一个通用的平台，可用于研究和开发新测定法，同时将可以移植到完全自动化的实验室chip测定中，最终可以用作服务测定的点。电化学发光检测在速度，信号到噪声以及辐射计和光度法技术方面具有明显的优势。在预设板上每孔多重多达10个分析物的能力在试剂和操作员时间方面是一个显着的节省。以下提案确定了一组参与转化研究和常规测定性能的主要用户（70％的仪器使用）和7个未成年人（30％的仪器使用），他们将主要将机器用于动物模型中的实验研究以及新的疾病生物标志物的研究和开发。 20名NIH资助的赠款的支持范围从几个多中心财团到DERC飞行员和可行性赠款持有者。提供了管理和维护仪器的计划。测定法的验证和质量控制将通过我们现有的参与糖尿病自身免疫性标准化计划从疾病控制中心通过糖尿病学会的免疫学进行。